Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.12 USD

96.12
370,120

+0.08 (0.08%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Here's Why You Should Invest in CVS Health (CVS) Stock Now

CVS Health's (CVS) solid cash position is encouraging. Strong 2019 PBM selling season is another upside.

    Henry Schein's 3 Investments to Fortify Dental Implant Arm

    Intra-Lock, Medentis Medical and Pro-Cam Implants jointly are likely to prove conducive to growth for Henry Schein's (HSIC) existing implant-based tooth replacement solutions line.

      Quest Diagnostics Plans a Buyout to Widen TB Testing Suite

      Quest Diagnostics (DGX) progresses well with regard to its strategy to grow inorganically.

        STERIS (STE) Strategic Growth Strong Amid Several Headwinds

        STERIS (STE) impresses with favorable underlying market trends apart from new products and service offerings. Yet, a severe competition lurking beneath is worrisome for the company.

          Sweta Jaiswal headshot

          4 MedTech Stocks to Counter Mounting US-China Trade Tensions

          In the wake of the impact of the U.S.-China trade war on the MedTech space, we have doubled down on some stocks which offer a safe haven to investors.

            Quest Diagnostics Inks Lab Service Deal With ReproSource

            Per agreement with ReproSource, Quest Diagnostics (DGX) to perform laboratory reference testing besides providing supply chain expertise.

              Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp

              Abbott's (ABT) life-changing High Sensitive Troponin-I test uses a biomarker, specific to the heart.

                Hologic's Focal Therapeutics Buyout to Boost Breast Health Arm

                Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.

                  Here's Why You Should Add Edwards Lifesciences Right Away

                  We are upbeat about the continued strength in Edwards Lifesciences' (EW) THVT business.

                    Will LabCorp's (LH) Food Solution Divestment Upset Sales?

                    LabCorp's (LH) lackluster outlook for 2018 includes the earlier-announced divestment of its Food Solutions business.

                      Neogen (NEOG) Earnings Beat, Revenues Lag Estimates in Q1

                      Accretive integrations and an expanding international footprint drive Neogen's (NEOG) earnings in Q1.

                        Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?

                        Style Box ETF report for FYC

                          Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?

                          Is (AMED) Outperforming Other Medical Stocks This Year?

                            Here's Why You Should Invest in Walgreens Boots Stock Now

                            Walgreens Boots (WBA) gains from tie-ups. The company's alliance with Express Scripts encourages.

                              Boston Scientific's FDA Nod for Eluvia Stent Expands PI Suite

                              Boston Scientific's (BSX) PMA approval for Eluvia Drug-Eluting Vascular Stent System will help boost the top line at the PI business.

                                Medtronic to Buy Mazor Robotics for Robotic Spine Surgery

                                The consolidation will combine Medtronic's (MDT) spine implants, navigation and intra-operative imaging technology with Mazor Robotics' robotic-assisted surgery (RAS) systems.

                                  Cardiovascular Systems Stealth 360 Peripheral OAS Goes Global

                                  Following the recent extension of its partnership with OrbusNeich, Cardiovascular Systems' (CSII) Stealth 360 Peripheral OAS is put to first commercial use in Hong Kong.

                                    Insulet Advances on Omnipod Reimbursement Update, Runs Risks

                                    Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.

                                      Here's Why You Should Hold on to Align Technology (ALGN) Now

                                      Continued strength in Align Technology's (ALGN) Invisalign volumes impresses. Overdependence on Invisalign Technology system is a concern.

                                        Zacks.com highlights: Insperity, Amedisys, Comfort Systems, Genesco and Forward Air

                                        Zacks.com highlights: Insperity, Amedisys, Comfort Systems, Genesco and Forward Air

                                          ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio

                                          ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.

                                            QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers

                                            Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.

                                              Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                                              Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.

                                                Kevin Matras headshot

                                                Winning Stock Picks from the Top 5 Industries with the Biggest Job Growth

                                                Kevin Matras goes over how to find winning stock-picking ideas in the government's 'boring' economic reports. Highlighted stocks include NSP, AMED, FIX, GEN and FWRD.

                                                  QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio

                                                  QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.